mitoNEET as a novel drug target for mitochondrial dysfunction.

mitoNEET as a novel drug target for mitochondrial dysfunction.

Geldenhuys Werner J; Leeper Thomas C; Carroll Richard T

Drug Discovery Today

2014

2014-10

Mitochondrial dysfunction plays an important part in the pathology of several diseases, including Alzheimer's disease and Parkinson's disease. Targeting mitochondrial proteins shows promise in treating and attenuating the neurodegeneration seen in these diseases, especially considering their complex and pleiotropic origins. Recently, the mitochondrial protein mitoNEET [also referred to as CDGSH iron sulfur domain 1 (CISD1)] has emerged as the mitochondrial target of thiazolidinedione drugs such as the antidiabetic pioglitazone. In this review, we evaluate the current understanding regarding how mitoNEET regulates cellular bioenergetics as well as the structural requirements for drug compound association with mitoNEET. With a clear understanding of mitoNEET function, it might be possible to develop therapeutic agents useful in several different diseases including neurodegeneration, breast cancer, diabetes and inflammation.

Animals; Drug Delivery Systems; Energy Metabolism; Humans; Mitochondria/*metabolism; Mitochondrial Proteins/chemistry/*metabolism; Protein Conformation; Thiazolidinediones/pharmacology

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

1601–1606

10

19